Divalproex Sodium Treatment of Women With Borderline Personality Disorder and Bipolar II Disorder: A Double-Blind Placebo-Controlled Pilot Study
J Clin Psychiatry 2002;63(5):442-446
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: The intent of this study was
to compare the efficacy and safety of divalproex sodium and placebo in the treatment of
women with borderline personality disorder and
comorbid bipolar II disorder.
Method: We conducted a
placebo-controlled double-blind study of divalproex sodium in
30 female subjects aged 18 to 40 years who met Revised Diagnostic Interview for Borderlines
and DSM-IV criteria for borderline personality
disorder and DSM-IV criteria for bipolar II
disorder. Subjects were randomly assigned to
divalproex sodium or placebo in a 2:1 manner.
Treatment duration was 6 months. Primary outcome
measures were changes on the interpersonal
sensitivity, anger/hostility, and depression scales of
the Symptom Checklist 90 (SCL-90) as well as the total score of the modified Overt
Aggression Scale (MOAS).
Results: Twenty subjects were randomly
assigned to divalproex sodium; 10 subjects to placebo. Using a
last-observation-carried-forward paradigm and controlling for baseline
severity, divalproex sodium proved to be superior to
placebo in diminishing interpersonal sensitivity
and anger/hostility as measured by the SCL-90 as well as overall aggression as measured by
the MOAS. Adverse effects were infrequent.
Conclusion: The results of this study
suggest that divalproex sodium may be a safe and
effective agent in the treatment of women with criteria-defined borderline personality disorder
and comorbid bipolar II disorder, significantly decreasing their irritability and anger, the
tempestuousness of their relationships, and their